DR. ALAN MARVIN KELLER M.D. NPI 1386696011

NPI Details

DR. Alan Marvin Keller, M.D. is a hematology and oncology internal medicine in Tulsa, OK. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Alan Marvin Keller, M.D. NPI is 1386696011. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

12697 E 51ST ST
TULSA, OK
ZIP 74146-236
Phone: (918) 505-3200
Fax: (918) 505-3253

The NPI 1386696011 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Magnesium level (HCPCS:83735)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Uric acid level, blood (HCPCS:84550)
• Phosphate level (HCPCS:84100)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml (HCPCS:A9579)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Reticulated (young) platelet measurement (HCPCS:85055)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Ct scan of chest with contrast (HCPCS:71260)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Blood creatinine level (HCPCS:82565)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Unclassified drugs (HCPCS:J3490)
• Ferritin (blood protein) level (HCPCS:82728)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Urine microalbumin (protein) analysis (HCPCS:82044)
• Mri scan of brain before and after contrast (HCPCS:70553)
• X-ray of chest, 2 views (HCPCS:71046)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Ct scan of chest without contrast (HCPCS:71250)
• Collection of blood sample from implanted device (HCPCS:36591)
• Nuclear medicine study whole body with ct scan (HCPCS:78816)
• Ct scan of abdomen and pelvis without contrast (HCPCS:74176)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Ct scan of soft tissue of neck with contrast (HCPCS:70491)
• Manual urinalysis test with examination using microscope, automated (HCPCS:81001)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)

The enumeration date for this NPI number is 5/17/2006 and was last updated on 5/8/2014.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: